ClinicalTrials.gg
CompletedNCT04713553Updated Dec 22, 2022Results posted

A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

A Phase 3 interventional study of BNT162b2 and BNT162b2.B.1.351 in SARS-CoV-2 Infection and COVID-19, sponsored by BioNTech SE. Completed at 17 sites in United States. Open to participants aged 12 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-22.

Sponsored by BioNTech SE · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,574
Allocation
Randomized
Ages
12 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.

Enrollment
8th of 54
1,574 · median 575
Started
2021
with 29 others
Phase 3
18 of 54
1 open now
Registered
6th of 54
by date
Lead sponsor
20 of 54
BioNTech SE

Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 8th largest by enrollment, is one of 30 that started in 2021, is one of 18 in phase 3, and was the 6th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About BNT162 Vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing BNT162 Vaccine in COVID-19, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, observer-blind study in healthy individuals.

The primary study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate (BNT162b2):

  • As a 30-microgram dose, administered from 1 of 4 manufacturing lots (batches)
  • As a 20-microgram dose, administered from 1 of the manufacturing lots
  • As a 2-dose (separated by 21 days) schedule
  • In people 12 through 50 years of age

The booster study will evaluate the safety, tolerability, and immunogenicity of 2 SARS-CoV-2 RNA vaccine candidates (BNT162b2 and BNT162b2.B.1.351):

  • Each as a 30-microgram dose
  • Each as a 1-dose booster vaccine, administered approximately 3 months after Dose 2
  • In people 18 through 50 years of age
03

Conditions studied

  • SARS-CoV-2 Infection
  • COVID-19

Keywords

  • COVID-19
  • Coronavirus
  • Vaccine
  • SARS-CoV-2
  • RNA Vaccine
  • BNT162b2
  • BNT162B2.1.B.351
04

Who can participate

Ages eligible
12 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary study: Male or female participants between the ages of 12 and 50 years, inclusive, at randomization.
  • Booster study: Male or female participants between the ages of 18 and 50 years, inclusive, at rerandomization.
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
  • Capable of giving personal signed /have parent(s)/legal guardian capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Known infection with , , or .
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.
  • Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19.

    . individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.

  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant or breastfeeding.
  • Primary study: Previous vaccination with any coronavirus vaccine.
  • Booster study: Previous vaccination with any coronavirus vaccine outside of this study.
  • Receipt of medications intended to prevent COVID-19.
  • Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic , eg, for cancer or an disease, or planned receipt throughout the study.
  • Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study.
  • Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.
  • Previous participation in other studies involving study intervention containing lipid nanoparticles.
  • Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

Additional Exclusion Criteria for the Booster study:

  • Current febrile illness (body temperature ≥100.4°F [≥38.0°C]) or other acute illness within 48 hours before study intervention administration.
  • Receipt of any seasonal or pandemic influenza vaccine within 14 days, or any other nonstudy vaccine within 28 days, before or after study intervention administration.
  • Receipt of short-term (\<14 days) systemic corticosteroids. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,574 participants (actual)

Study arms

  • Experimental
    Arm 1

    30-microgram dose of US manufactured drug substance (Lot 1)

    Biological: BNT162b2

  • Experimental
    Arm 2

    30-microgram dose of US manufactured drug substance (Lot 2)

    Biological: BNT162b2

  • Experimental
    Arm 3

    30-microgram dose of US manufactured drug substance (Lot 3)

    Biological: BNT162b2

  • Experimental
    Arm 4

    30-microgram dose of EU manufactured drug substance (Lot 4)

    Biological: BNT162b2

  • Experimental
    Arm 5

    20-microgram dose of US manufactured drug substance (corresponding to Arm 1, 2 or 3 lot)

    Biological: BNT162b2

  • Experimental
    Booster 1: BNT162b2

    30-microgram dose

    Biological: BNT162b2

  • Experimental
    Booster 2: BNT162b2.B.1.351

    30-microgram dose

    Biological: BNT162b2.B.1.351

Interventions

  • BiologicalBNT162b2

    Intramuscular injection

  • BiologicalBNT162b2.B.1.351

    Intramuscular injection

06

What researchers measure

Primary outcomes

  1. Geometric Mean Ratios (GMRs) of Full-Length S-Binding Immunoglobulin G (IgG) Concentrations Between Individual US Lots 1, 2, and 3 at 1 Month After Dose 2: Primary Study

    Geometric mean concentration of full-length S-binding IgG level for individual US lots (US lots 1, 2, and 3) was determined and reported in the descriptive section. Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. GMRs were reported in the statistical analysis section and was calculated as ratio of Geometric Mean Concentrations (GMCs) of individual US Lots BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3.

    Time frame: 1 Month after Dose 2

  2. Geometric Mean Ratios (GMRs) of Full-Length S-Binding IgG Concentrations Between EU Lot and Pooled US Lots at 1 Month After Dose 2: Primary Study

    Geometric mean concentration of full-length S-binding IgG level for EU lot and pooled US lots (BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3 reporting arm) were determined and reported in the descriptive section. Assay results below the LLOQ were set to 0.5\*LLOQ. GMRs were reported in the statistical analysis section and was calculated as ratios of GMCs of BNT162b2 30 mcg: EU Lot and pooled US Lots (BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3 reporting arm).

    Time frame: 1 Month after Dose 2

  3. Geometric Mean Ratios (GMRs) of SARS-CoV-2 Neutralizing Titers Between 20-microgram Dose and 30-microgram Dose at 1 Month After Dose 2: Primary Study

    Geometric mean titer for SARS-CoV-2 neutralizing titers for 20 mcg dose and 30 mcg dose of US Lot 1 was determined and reported in the descriptive section. GMTs and 2-sided 95% CIs were calculated by exponentiating the least square (LS) mean of the titers and corresponding CIs based on linear regression model. Assay results below the LLOQ were set to 0.5\*LLOQ. GMRs were reported in the statistical analysis section and were calculated as the ratio of geometric mean titer of the 20-mcg dose (US Lot 1) to the geometric mean titer of the 30 mcg dose (US Lot 1).

    Time frame: 1 Month after Dose 2

  4. Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study

    Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 1. Redness, swelling, and pain at injection site after Dose 1 were reported.

    Time frame: Within 7 days after Dose 1

  5. Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Primary Study

    Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 2. Redness, swelling, and pain at injection site after Dose 2 were reported.

    Time frame: Within 7 days after Dose 2

  6. Percentage of Participants With Local Reactions Within 7 Days After Any Dose: Primary Study

    Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after each vaccination. Redness, swelling, and pain at injection site after any dose were reported.

    Time frame: Within 7 days after any dose

  7. Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Booster Study

    Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 3. Redness, swelling, and pain at injection site after Dose 3 were reported.

    Time frame: Within 7 days after Dose 3

  8. Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Primary Study

    Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 degree Celsius (C) and categorized as \>=38.0 to 38.4 C; \>38.4 to 38.9 C; \>38.9 to 40.0 C; \>40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 1 were reported.

    Time frame: Within 7 days after Dose 1

  9. Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Primary Study

    Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 C and categorized as \>=38.0 to 38.4 C; \>38.4 to 38.9 C; \>38.9 to 40.0 C; \>40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 2 were reported.

    Time frame: Within 7 days after Dose 2

  10. Percentage of Participants With Systemic Events Within 7 Days After Any Dose: Primary Study

    Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 C and categorized as \>=38.0 to 38.4 C; \>38.4 to 38.9 C; \>38.9 to 40.0 C; \>40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after any dose were reported.

    Time frame: Within 7 days after any dose

  11. Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Booster Study

    Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 C and categorized as \>=38.0 to 38.4 C; \>38.4 to 38.9 C; \>38.9 to 40.0 C; \>40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 3 were reported.

    Time frame: Within 7 days after Dose 3

  12. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 2: Primary Study

    An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.

    Time frame: Day 1 of Dose 1 up to 1 Month after Dose 2 (for a maximum of 2 months)

  13. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 3 to 1 Month After Dose 3: Booster Study

    An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.

    Time frame: From Dose 3 to 1 Month after Dose 3 (for a maximum of 35 days)

  14. Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain at Baseline: Booster Study

    GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

    Time frame: Baseline (prior to Dose 1 of Primary study)

  15. Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Month After Dose 2: Booster Study

    GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

    Time frame: 1 Month after Dose 2 of primary study

  16. Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain Before Dose 3: Booster Study

    GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

    Time frame: Before Dose 3

  17. Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Week After Dose 3: Booster Study

    GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

    Time frame: 1 Week after Dose 3

  18. Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Month After Dose 3: Booster Study

    GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

    Time frame: 1 Month after Dose 3

  19. Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain at Baseline: Booster Study

    GMTs and 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).

    Time frame: Baseline (prior to Dose 1 of Primary study)

  20. Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Month After Dose 2: Booster Study

    GMTs and 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).

    Time frame: 1 Month after Dose 2 of primary study

  21. Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain Before Dose 3: Booster Study

    GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

    Time frame: Before Dose 3

  22. Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Week After Dose 3: Booster Study

    GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

    Time frame: 1 Week after Dose 3

  23. Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Month After Dose 3: Booster Study

    GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

    Time frame: 1 Month after Dose 3

  24. Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels at Baseline: Booster Study

    GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Baseline (prior to Dose 1 of Primary study)

  25. Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Month After Dose 2: Booster Study

    GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: 1 Month after Dose 2 of primary study

  26. Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels Before Dose 3: Booster Study

    GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Before Dose 3

  27. Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Week After Dose 3: Booster Study

    GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: 1 Week after Dose 3

  28. Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Month After Dose 3: Booster Study

    GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: 1 Month after Dose 3

  29. Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study

    GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 week after Dose 3 to the geometric mean concentration of IgG at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: From 1 Month after Dose 2 to 1 Week after Dose 3

  30. Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study

    GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 3 to the geometric mean concentration of IgG at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: From 1 Month after Dose 2 to 1 Month after Dose 3

  31. Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels Before Dose 3 to 1 Week After Dose 3: Booster Study

    GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 week after Dose 3 to the geometric mean concentration of IgG before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Before Dose 3 to 1 Week after Dose 3

  32. Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels Before Dose 3 to 1 Month After Dose 3: Booster Study

    GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 3 to the geometric mean concentration of IgG before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Before Dose 3 to 1 Month after Dose 3

  33. Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study

    GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: From 1 Month after Dose 2 to 1 Week after Dose 3

  34. Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study

    GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: From 1 Month after Dose 2 to 1 Month after Dose 3

  35. Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain Before Dose 3 to 1 Week After Dose 3: Booster Study

    GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Before Dose 3 to 1 Week after Dose 3

  36. Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain Before Dose 3 to 1 Month After Dose 3: Booster Study

    GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Before Dose 3 to 1 Month after Dose 3

  37. Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study

    GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after dose 2. GMFRs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).

    Time frame: From 1 Month after Dose 2 to 1 Week after Dose 3

  38. Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study

    GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after dose 2. GMFRs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).

    Time frame: From 1 Month after Dose 2 to 1 Month after Dose 3

  39. Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain Before Dose 3 to 1 Week After Dose 3: Booster Study

    GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Before Dose 3 to 1 Week after Dose 3

  40. Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain Before Dose 3 to 1 Month After Dose 3: Booster Study

    GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Before Dose 3 to 1 Month after Dose 3

  41. Percentage of Participants With Seroresponse to Reference Strain at 1 Month After Dose 2: Booster Study

    Seroresponse was defined as greater than equal to (\>=) 4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of \>=4\*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: 1 Month after Dose 2

  42. Percentage of Participants With Seroresponse to Reference Strain Before Dose 3: Booster Study

    Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of \>=4\*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: Before Dose 3

  43. Percentage of Participants With Seroresponse to Reference Strain 1 Week After Dose 3: Booster Study

    Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of \>=4\*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: 1 Week after Dose 3

  44. Percentage of Participants With Seroresponse to Reference Strain 1 Month After Dose 3: Booster Study

    Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of \>=4\*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: 1 Month after Dose 3

  45. Percentage of Participants With Seroresponse to B.1.351 Variant Strain at 1 Month After Dose 2: Booster Study

    Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.

    Time frame: 1 Month after Dose 2

  46. Percentage of Participants With Seroresponse to B.1.351 Variant Strain Before Dose 3: Booster Study

    Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.

    Time frame: Before Dose 3

  47. Percentage of Participants With Seroresponse to B.1.351 Variant Strain 1 Week After Dose 3: Booster Study

    Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.

    Time frame: 1 Week after Dose 3

  48. Percentage of Participants With Seroresponse to B.1.351 Variant Strain 1 Month After Dose 3: Booster Study

    Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.

    Time frame: 1 Month after Dose 3

Secondary outcomes

  1. Geometric Mean Concentrations (GMCs) of Full-Length S-Binding IgG Levels at Baseline and 1 Month After Dose 2 for 30 mcg Dose of BNT162b2: Primary Study

    GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\* LLOQ.

    Time frame: Baseline (before Dose 1), 1 Month after Dose 2

  2. Geometric Mean Fold Rises (GMFRs) in Full-Length S-Binding lgG Levels From Baseline to 1 Month After Dose 2 for 30 mcg Dose of BNT162b2: Primary Study

    GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 2 to the geometric mean concentration of IgG at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: From Baseline (before Dose 1) up to 1 Month after Dose 2

  3. Geometric Mean Titers (GMT) of SARS-CoV-2 Neutralizing Titers at Baseline and 1 Month After Dose 2 for 20 mcg and 30 mcg Dose of BNT162b2 From US Lot 1: Primary Study

    GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\* LLOQ.

    Time frame: Baseline (before Dose 1), 1 Month after Dose 2

  4. Geometric Mean Fold Rises (GMFRs) in SARS-CoV-2 Neutralizing Titers From Baseline to 1 Month After Dose 2 for 20 mcg and 30 mcg Dose of BNT162b2 From US Lot 1: Primary Study

    GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 at 1 month after Dose 2 to the geometric mean titers of SARS-CoV-2 at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\* LLOQ.

    Time frame: From Baseline (before Dose 1) up to 1 Month after Dose 2

07

Results

Posted Dec 22, 2022

Participant flow

This study was conducted in two parts: primary study and booster study.

Primary Study (2 Months)
Participant flow — Primary Study (2 Months)
MilestoneBNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3BNT162b2 30 mcg: EU LotBNT162b2 20 mcg: US Lot 1BNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Started35135234717335100
Treated35135234617335100
Completed34734634417134900
Not completed4632200
Withdrew: Withdrawal by subject2300100
Withdrew: Withdrawal by parent/guardian0001000
Withdrew: Other1200100
Withdrew: Lost to follow-up1121000
Withdrew: Inclusion criteria not met0010000
Booster Study (1 Month)
Participant flow — Booster Study (1 Month)
MilestoneBNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3BNT162b2 30 mcg: EU LotBNT162b2 20 mcg: US Lot 1BNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Started000003131
Completed000003131
Not completed0000000

Outcome measures

PrimaryGeometric Mean Ratios (GMRs) of Full-Length S-Binding Immunoglobulin G (IgG) Concentrations Between Individual US Lots 1, 2, and 3 at 1 Month After Dose 2: Primary Study

Geometric mean concentration of full-length S-binding IgG level for individual US lots (US lots 1, 2, and 3) was determined and reported in the descriptive section. Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. GMRs were reported in the statistical analysis section and was calculated as ratio of Geometric Mean Concentrations (GMCs) of individual US Lots BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3.

Time frame:
1 Month after Dose 2
Reported as:
Geometric mean · Unit per milliliter
Geometric Mean Ratios (GMRs) of Full-Length S-Binding Immunoglobulin G (IgG) Concentrations Between Individual US Lots 1, 2, and 3 at 1 Month After Dose 2: Primary Study
Unit per milliliterBNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3
Geometric Mean Ratios (GMRs) of Full-Length S-Binding Immunoglobulin G (IgG) Concentrations Between Individual US Lots 1, 2, and 3 at 1 Month After Dose 2: Primary Study6299.5 ± 5835.46231.9 ± 5763.76774.8 ± 6264.9
Statistical analysis
  • BNT162b2 30 mcg: US Lot 1 vs BNT162b2 30 mcg: US Lot 2 · Geometric mean ratio: 1.01 · 95% CI 0.91 to 1.13GMRs and corresponding 2-sided 95% CIs were calculated by exponentiating difference in LS means and corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of age and vaccine group.
  • BNT162b2 30 mcg: US Lot 1 vs BNT162b2 30 mcg: US Lot 3 · Geometric mean ratio: 0.93 · 95% CI 0.83 to 1.04GMRs and corresponding 2-sided 95% CIs were calculated by exponentiating difference in LS means and corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of age and vaccine group.
  • BNT162b2 30 mcg: US Lot 2 vs BNT162b2 30 mcg: US Lot 3 · Geometric mean ratio: 0.92 · 95% CI 0.82 to 1.03GMRs and corresponding 2-sided 95% CIs were calculated by exponentiating difference in LS means and corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of age and vaccine group.
PrimaryGeometric Mean Ratios (GMRs) of Full-Length S-Binding IgG Concentrations Between EU Lot and Pooled US Lots at 1 Month After Dose 2: Primary Study

Geometric mean concentration of full-length S-binding IgG level for EU lot and pooled US lots (BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3 reporting arm) were determined and reported in the descriptive section. Assay results below the LLOQ were set to 0.5\*LLOQ. GMRs were reported in the statistical analysis section and was calculated as ratios of GMCs of BNT162b2 30 mcg: EU Lot and pooled US Lots (BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3 reporting arm).

Time frame:
1 Month after Dose 2
Reported as:
Geometric mean · Unit per milliliter
Geometric Mean Ratios (GMRs) of Full-Length S-Binding IgG Concentrations Between EU Lot and Pooled US Lots at 1 Month After Dose 2: Primary Study
Unit per milliliterBNT162b2 30 mcg: EU LotPooled US Lots
Geometric Mean Ratios (GMRs) of Full-Length S-Binding IgG Concentrations Between EU Lot and Pooled US Lots at 1 Month After Dose 2: Primary Study6098.6 (5474.7 to 6793.7)6428.8 (6149.5 to 6720.7)
Statistical analysis
  • BNT162b2 30 mcg: EU Lot vs Pooled US Lots · Geometric mean ratio: 0.95 · 95% CI 0.84 to 1.07GMRs and corresponding 2-sided 95% CIs were calculated by exponentiating difference in LS means and corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of age and vaccine group.
PrimaryGeometric Mean Ratios (GMRs) of SARS-CoV-2 Neutralizing Titers Between 20-microgram Dose and 30-microgram Dose at 1 Month After Dose 2: Primary Study

Geometric mean titer for SARS-CoV-2 neutralizing titers for 20 mcg dose and 30 mcg dose of US Lot 1 was determined and reported in the descriptive section. GMTs and 2-sided 95% CIs were calculated by exponentiating the least square (LS) mean of the titers and corresponding CIs based on linear regression model. Assay results below the LLOQ were set to 0.5\*LLOQ. GMRs were reported in the statistical analysis section and were calculated as the ratio of geometric mean titer of the 20-mcg dose (US Lot 1) to the geometric mean titer of the 30 mcg dose (US Lot 1).

Time frame:
1 Month after Dose 2
Reported as:
Geometric mean · Titer
Geometric Mean Ratios (GMRs) of SARS-CoV-2 Neutralizing Titers Between 20-microgram Dose and 30-microgram Dose at 1 Month After Dose 2: Primary Study
TiterBNT162b2 30 mcg: US Lot 1BNT162b2 20 mcg: US Lot 1
Geometric Mean Ratios (GMRs) of SARS-CoV-2 Neutralizing Titers Between 20-microgram Dose and 30-microgram Dose at 1 Month After Dose 2: Primary Study906.3 (847.8 to 968.9)976.6 (914.1 to 1043.4)
Statistical analysis
  • BNT162b2 30 mcg: US Lot 1 vs BNT162b2 20 mcg: US Lot 1 · Geometric mean ratio: 0.93 · 95% CI 0.84 to 1.02GMRs were calculated by exponentiating the difference in LS means and corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of age and vaccine group
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study

Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 1. Redness, swelling, and pain at injection site after Dose 1 were reported.

Time frame:
Within 7 days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study
Percentage of participantsBNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3Pooled US LotsBNT162b2 30 mcg: EU LotBNT162b2 20 mcg: US Lot 1
Redness1.1 (0.3 to 2.9)2.0 (0.8 to 4.1)2.9 (1.4 to 5.3)2.0 (1.2 to 3.0)2.3 (0.6 to 5.8)2.0 (0.8 to 4.1)
Swelling2.0 (0.8 to 4.1)3.7 (2.0 to 6.2)3.8 (2.0 to 6.4)3.1 (2.2 to 4.4)2.9 (0.9 to 6.6)3.4 (1.8 to 5.9)
Pain at Injection Site82.9 (78.6 to 86.7)79.3 (74.6 to 83.4)84.6 (80.4 to 88.3)82.3 (79.8 to 84.5)86.1 (80.1 to 90.9)78.1 (73.4 to 82.3)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 2: Primary Study

Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 2. Redness, swelling, and pain at injection site after Dose 2 were reported.

Time frame:
Within 7 days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Primary Study
Percentage of participantsBNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3Pooled US LotsBNT162b2 30 mcg: EU LotBNT162b2 20 mcg: US Lot 1
Redness3.7 (2.0 to 6.3)4.0 (2.2 to 6.6)4.4 (2.5 to 7.1)4.0 (2.9 to 5.4)2.9 (1.0 to 6.7)3.2 (1.6 to 5.6)
Swelling4.9 (2.9 to 7.7)6.0 (3.8 to 9.0)4.7 (2.7 to 7.5)5.2 (3.9 to 6.7)3.5 (1.3 to 7.4)3.7 (2.0 to 6.3)
Pain at Injection Site80.2 (75.7 to 84.3)77.7 (73.0 to 82.0)83.1 (78.7 to 86.9)80.3 (77.8 to 82.7)77.3 (70.3 to 83.4)79.6 (75.0 to 83.7)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Any Dose: Primary Study

Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after each vaccination. Redness, swelling, and pain at injection site after any dose were reported.

Time frame:
Within 7 days after any dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Any Dose: Primary Study
Percentage of participantsBNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3Pooled US LotsBNT162b2 30 mcg: EU LotBNT162b2 20 mcg: US Lot 1
Redness4.6 (2.6 to 7.3)5.4 (3.3 to 8.3)6.6 (4.2 to 9.8)5.5 (4.2 to 7.1)4.6 (2.0 to 8.9)4.6 (2.6 to 7.3)
Swelling6.0 (3.7 to 9.0)8.8 (6.1 to 12.3)7.2 (4.7 to 10.5)7.3 (5.8 to 9.1)4.6 (2.0 to 8.9)6.3 (4.0 to 9.3)
Pain at Injection Site90.9 (87.4 to 93.7)85.8 (81.7 to 89.3)91.1 (87.6 to 93.8)89.2 (87.2 to 91.0)91.3 (86.1 to 95.1)89.5 (85.8 to 92.5)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 3: Booster Study

Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 3. Redness, swelling, and pain at injection site after Dose 3 were reported.

Time frame:
Within 7 days after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Booster Study
Percentage of participantsBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Redness9.7 ± 2.03.2 ± 0.1
Swelling6.5 ± 0.86.5 ± 0.8
Pain at Injection site90.3 ± 74.293.5 ± 78.6
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 1: Primary Study

Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 degree Celsius (C) and categorized as \>=38.0 to 38.4 C; \>38.4 to 38.9 C; \>38.9 to 40.0 C; \>40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 1 were reported.

Time frame:
Within 7 days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Primary Study
Percentage of participantsBNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3Pooled US LotsBNT162b2 30 mcg: EU LotBNT162b2 20 mcg: US Lot 1
Fever >=38.0 C0.3 (0.0 to 1.6)0 (0.0 to 1.0)2.0 (0.8 to 4.1)0.8 (0.3 to 1.5)1.2 (0.1 to 4.1)0 (0.0 to 1.0)
Fever >=38.0 C to 38.4 C0.3 (0.0 to 1.6)0 (0.0 to 1.0)1.2 (0.3 to 2.9)0.5 (0.2 to 1.1)0.6 (0.0 to 3.2)0 (0.0 to 1.0)
Fever >38.4 C to 38.9 C0 (0.0 to 1.0)0 (0.0 to 1.0)0.6 (0.1 to 2.1)0.2 (0.0 to 0.7)0.6 (0.0 to 3.2)0 (0.0 to 1.0)
Fever >38.9 C to 40.0 C0 (0.0 to 1.0)0 (0.0 to 1.0)0.3 (0.0 to 1.6)0.1 (0.0 to 0.5)0 (0.0 to 2.1)0 (0.0 to 1.0)
Fever >40.0 C0 (0.0 to 1.0)0 (0.0 to 1.0)1 (0.0 to 1.1)0 (0.0 to 0.4)0 (0.0 to 2.1)0 (0.0 to 1.0)
Fatigue53.3 (47.9 to 58.6)45.5 (40.2 to 50.8)50.7 (45.3 to 56.1)49.8 (46.7 to 52.9)49.1 (41.5 to 56.8)49.0 (43.7 to 54.4)
Headache36.2 (31.1 to 41.5)32.7 (27.8 to 37.8)33.3 (28.4 to 38.6)34.1 (31.2 to 37.0)38.7 (31.4 to 46.4)35.6 (30.6 to 40.9)
Chills8.5 (5.8 to 12.0)7.7 (5.1 to 11.0)10.1 (7.2 to 13.8)8.8 (7.1 to 10.7)8.1 (4.5 to 13.2)6.8 (4.4 to 10.0)
Vomiting0.6 (0.1 to 2.0)0.6 (0.1 to 2.0)1.2 (0.3 to 2.9)0.8 (0.3 to 1.5)0.6 (0.0 to 3.2)0.9 (0.2 to 2.5)
Diarrhea9.7 (6.8 to 13.3)8.0 (5.4 to 11.3)7.8 (5.2 to 11.2)8.5 (6.9 to 10.3)9.2 (5.4 to 14.6)10.0 (7.0 to 13.6)
New/worsened muscle pain14.5 (11.0 to 18.7)13.1 (9.7 to 17.0)16.5 (12.8 to 20.9)14.7 (12.6 to 17.0)17.3 (12.0 to 23.8)16.2 (12.5 to 20.5)
New/worsened joint pain6.8 (4.4 to 10.0)6.5 (4.2 to 9.6)7.0 (4.5 to 10.2)6.8 (5.3 to 8.5)7.5 (4.1 to 12.5)6.6 (4.2 to 9.7)
Use of antipyretic/analgesic medication16.8 (13.0 to 21.1)14.5 (11.0 to 18.6)18.8 (14.9 to 23.4)16.7 (14.5 to 19.1)22.0 (16.0 to 28.9)18.2 (14.3 to 22.7)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 2: Primary Study

Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 C and categorized as \>=38.0 to 38.4 C; \>38.4 to 38.9 C; \>38.9 to 40.0 C; \>40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 2 were reported.

Time frame:
Within 7 days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Primary Study
Percentage of participantsBNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3Pooled US LotsBNT162b2 30 mcg: EU LotBNT162b2 20 mcg: US Lot 1
Fever >=38.0 C7.2 (4.7 to 10.4)6.3 (4.0 to 9.4)6.7 (4.3 to 9.9)6.7 (5.3 to 8.4)8.7 (5.0 to 14.0)5.7 (3.5 to 8.7)
Fever >=38.0 C to 38.4 C4.6 (2.6 to 7.3)3.4 (1.8 to 5.9)3.2 (1.6 to 5.7)3.7 (2.7 to 5.1)6.4 (3.2 to 11.2)4.3 (2.4 to 7.0)
Fever >38.4 C to 38.9 C2.0 (0.8 to 4.1)2.0 (0.8 to 4.1)2.3 (1.0 to 4.5)2.1 (1.3 to 3.2)1.2 (0.1 to 4.1)1.4 (0.5 to 3.3)
Fever >38.9 C to 40.0 C0.6 (0.1 to 2.1)0.9 (0.2 to 2.5)0.9 (0.2 to 2.5)0.8 (0.3 to 1.5)1.2 (0.1 to 4.1)0 (0.0 to 1.1)
Fever >40.0 C0 (0.0 to 1.1)0 (0.0 to 1.0)0.3 (0.0 to 1.6)0.1 (0.0 to 0.5)0 (0.0 to 2.1)0 (0.0 to 2.1)
Fatigue69.9 (64.8 to 74.7)66.6 (61.4 to 71.5)71.4 (66.3 to 76.2)69.3 (66.4 to 72.1)69.8 (62.3 to 76.5)66.7 (61.4 to 71.6)
Headache57.0 (51.6 to 62.3)56.6 (51.2 to 61.8)56.9 (51.4 to 62.2)56.8 (53.7 to 59.8)56.4 (48.6 to 63.9)50.6 (45.2 to 55.9)
Chills28.1 (23.4 to 33.1)31.1 (26.3 to 36.3)33.8 (28.8 to 39.1)31.0 (28.2 to 33.9)28.5 (21.9 to 35.9)23.6 (19.2 to 28.4)
Vomiting2.3 (1.0 to 4.5)1.4 (0.5 to 3.3)2.3 (1.0 to 4.5)2.0 (1.3 to 3.1)1.7 (0.4 to 5.0)1.4 (0.5 to 3.3)
Diarrhea8.3 (5.6 to 11.7)9.1 (6.3 to 12.7)7.9 (5.3 to 11.2)8.4 (6.8 to 10.3)9.3 (5.4 to 14.7)6.9 (4.5 to 10.1)
New/worsened muscle pain32.7 (27.8 to 37.9)38.6 (33.4 to 43.9)35.6 (30.5 to 40.9)35.6 (32.7 to 38.6)36.0 (28.9 to 43.7)35.6 (30.6 to 40.9)
New/worsened joint pain19.2 (15.2 to 23.7)24.6 (20.2 to 29.4)19.2 (15.2 to 23.8)21.0 (18.6 to 23.6)19.2 (13.6 to 25.9)19.5 (15.5 to 24.1)
Use of antipyretic/analgesic medication35.2 (30.2 to 40.5)41.1 (35.9 to 46.5)40.8 (35.6 to 46.2)39.1 (36.1 to 42.1)41.9 (34.4 to 49.6)37.9 (32.8 to 43.3)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Any Dose: Primary Study

Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 C and categorized as \>=38.0 to 38.4 C; \>38.4 to 38.9 C; \>38.9 to 40.0 C; \>40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after any dose were reported.

Time frame:
Within 7 days after any dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Any Dose: Primary Study
Percentage of participantsBNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3Pooled US LotsBNT162b2 30 mcg: EU LotBNT162b2 20 mcg: US Lot 1
Fever >=38.0 C7.4 (4.9 to 10.7)6.3 (4.0 to 9.3)8.4 (5.7 to 11.8)7.3 (5.8 to 9.1)9.2 (5.4 to 14.6)5.7 (3.5 to 8.7)
Fever >=38.0 C to 38.4 C4.8 (2.8 to 7.6)3.4 (1.8 to 5.9)4.0 (2.2 to 6.7)4.1 (3.0 to 5.5)6.4 (3.2 to 11.1)4.3 (2.4 to 7.0)
Fever >38.4 C to 38.9 C2.0 (0.8 to 4.1)2.0 (0.8 to 4.1)2.9 (1.4 to 5.2)2.3 (1.5 to 3.4)1.7 (0.4 to 5.0)1.4 (0.5 to 3.3)
Fever >38.9 C to 40.0 C0.6 (0.1 to 2.0)0.9 (0.2 to 2.5)1.2 (0.3 to 2.9)0.9 (0.4 to 1.6)1.2 (0.1 to 4.1)0 (0.0 to 1.0)
Fever >40.0 C0 (0.0 to 1.0)0 (0.0 to 1.0)0.3 (0.0 to 1.6)0.1 (0.0 to 0.5)0 (0.0 to 2.1)0 (0.0 to 1.0)
Fatigue78.6 (74.0 to 82.8)73.6 (68.6 to 78.1)81.0 (76.4 to 85.0)77.8 (75.1 to 80.3)76.9 (69.9 to 82.9)75.5 (70.7 to 79.9)
Headache66.7 (61.5 to 71.6)65.1 (59.8 to 70.0)64.3 (59.0 to 69.3)65.4 (62.4 to 68.3)68.8 (61.3 to 75.6)63.8 (58.5 to 68.9)
Chills32.8 (27.9 to 37.9)34.1 (29.1 to 39.3)37.2 (32.1 to 42.5)34.7 (31.8 to 37.7)32.4 (25.5 to 39.9)26.2 (21.7 to 31.1)
Vomiting2.8 (1.4 to 5.2)2.0 (0.8 to 4.1)3.5 (1.8 to 6.0)2.8 (1.9 to 3.9)2.3 (0.6 to 5.8)2.3 (1.0 to 4.4)
Diarrhea16.2 (12.5 to 20.5)14.2 (10.7 to 18.3)13.8 (10.4 to 17.9)14.8 (12.7 to 17.1)15.0 (10.1 to 21.2)15.4 (11.8 to 19.6)
New/worsened muscle pain38.7 (33.6 to 44.1)43.5 (38.2 to 48.8)43.2 (37.9 to 48.6)41.8 (38.8 to 44.9)43.9 (36.4 to 51.7)40.5 (35.3 to 45.8)
New/worsened joint pain23.4 (19.0 to 28.1)27.3 (22.7 to 32.2)23.9 (19.5 to 28.8)24.9 (22.3 to 27.6)24.3 (18.1 to 31.4)22.2 (18.0 to 26.9)
Use of antipyretic/analgesic medication41.9 (36.7 to 47.2)43.8 (38.5 to 49.1)46.4 (41.1 to 51.8)44.0 (41.0 to 47.1)51.4 (43.7 to 59.1)43.6 (38.3 to 49.0)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 3: Booster Study

Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 C and categorized as \>=38.0 to 38.4 C; \>38.4 to 38.9 C; \>38.9 to 40.0 C; \>40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 3 were reported.

Time frame:
Within 7 days after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Booster Study
Percentage of participantsBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Fever >=38.0 C3.2 (0.1 to 16.7)6.5 (0.8 to 21.4)
Fever >=38.0 C to 38.4 C0 (0.0 to 11.2)6.5 (0.8 to 21.4)
Fever >38.4 C to 38.9 C3.2 (0.1 to 16.7)0 (0.0 to 11.2)
Fever >38.9 C to 40.0 C0 (0.0 to 11.2)0 (0.0 to 11.2)
Fever >40.0 C0 (0.0 to 11.2)0 (0.0 to 11.2)
Fatigue67.7 (48.6 to 83.3)83.9 (66.3 to 94.5)
Headache41.9 (24.5 to 60.9)58.1 (39.1 to 75.5)
Chills25.8 (11.9 to 44.6)19.4 (7.5 to 37.5)
Vomiting3.2 (0.1 to 16.7)0 (0.0 to 11.2)
Diarrhea16.1 (5.5 to 33.7)6.5 (0.8 to 21.4)
New/worsened muscle pain41.9 (24.5 to 60.9)19.4 (7.5 to 37.5)
New/worsened joint pain12.9 (3.6 to 29.8)12.9 (3.6 to 29.8)
Use of antipyretic/analgesic medication32.3 (16.7 to 51.4)35.5 (19.2 to 54.6)
PrimaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 2: Primary Study

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.

Time frame:
Day 1 of Dose 1 up to 1 Month after Dose 2 (for a maximum of 2 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 2: Primary Study
Percentage of participantsBNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3Pooled US LotsBNT162b2 30 mcg: EU LotBNT162b2 20 mcg: US Lot 1
AEs5.46.05.25.510.46.8
SAEs000.30.10.60
PrimaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 3 to 1 Month After Dose 3: Booster Study

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.

Time frame:
From Dose 3 to 1 Month after Dose 3 (for a maximum of 35 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 3 to 1 Month After Dose 3: Booster Study
Percentage of participantsBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
AEs6.53.2
SAEs00
PrimaryGeometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain at Baseline: Booster Study

GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

Time frame:
Baseline (prior to Dose 1 of Primary study)
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain at Baseline: Booster Study
TiterBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain at Baseline: Booster Study20.5 (20.5 to 20.5)20.5 (20.5 to 20.5)
PrimaryGeometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Month After Dose 2: Booster Study

GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

Time frame:
1 Month after Dose 2 of primary study
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Month After Dose 2: Booster Study
TiterBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Month After Dose 2: Booster Study971.4 (750.5 to 1257.4)749.0 (575.2 to 975.3)
PrimaryGeometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain Before Dose 3: Booster Study

GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

Time frame:
Before Dose 3
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain Before Dose 3: Booster Study
TiterBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain Before Dose 3: Booster Study263.5 (186.9 to 371.3)224.2 (176.4 to 285.1)
PrimaryGeometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Week After Dose 3: Booster Study

GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

Time frame:
1 Week after Dose 3
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Week After Dose 3: Booster Study
TiterBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Week After Dose 3: Booster Study2159.3 (1568.4 to 2972.8)1283.4 (939.4 to 1753.5)
PrimaryGeometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Month After Dose 3: Booster Study

GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

Time frame:
1 Month after Dose 3
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Month After Dose 3: Booster Study
TiterBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Month After Dose 3: Booster Study2035.5 (1502.2 to 2758.1)943.3 (699.1 to 1272.7)
PrimaryGeometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain at Baseline: Booster Study

GMTs and 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).

Time frame:
Baseline (prior to Dose 1 of Primary study)

No measurements were reported for this outcome.

PrimaryGeometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Month After Dose 2: Booster Study

GMTs and 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).

Time frame:
1 Month after Dose 2 of primary study

No measurements were reported for this outcome.

PrimaryGeometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain Before Dose 3: Booster Study

GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

Time frame:
Before Dose 3
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain Before Dose 3: Booster Study
TiterBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain Before Dose 3: Booster Study103.0 (75.4 to 140.8)94.0 (67.5 to 130.8)
PrimaryGeometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Week After Dose 3: Booster Study

GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

Time frame:
1 Week after Dose 3
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Week After Dose 3: Booster Study
TiterBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Week After Dose 3: Booster Study1614.1 (1172.8 to 2221.6)1729.8 (1160.0 to 2579.4)
PrimaryGeometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Month After Dose 3: Booster Study

GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

Time frame:
1 Month after Dose 3
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Month After Dose 3: Booster Study
TiterBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Month After Dose 3: Booster Study1358.4 (968.5 to 1905.1)1411.1 (950.1 to 2095.9)
PrimaryGeometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels at Baseline: Booster Study

GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Baseline (prior to Dose 1 of Primary study)
Reported as:
Geometric mean · Unit per milliliter
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels at Baseline: Booster Study
Unit per milliliterBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels at Baseline: Booster Study3.4 (2.0 to 5.7)3.4 (2.3 to 5.1)
PrimaryGeometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Month After Dose 2: Booster Study

GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
1 Month after Dose 2 of primary study
Reported as:
Geometric mean · Unit per milliliter
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Month After Dose 2: Booster Study
Unit per milliliterBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Month After Dose 2: Booster Study6529.1 (5212.9 to 8177.6)3796.9 (1899.8 to 7588.4)
PrimaryGeometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels Before Dose 3: Booster Study

GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Before Dose 3
Reported as:
Geometric mean · Unit per milliliter
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels Before Dose 3: Booster Study
Unit per milliliterBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels Before Dose 3: Booster Study1834.5 (1458.5 to 2307.5)1851.6 (1441.9 to 2377.8)
PrimaryGeometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Week After Dose 3: Booster Study

GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
1 Week after Dose 3
Reported as:
Geometric mean · Unit per milliliter
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Week After Dose 3: Booster Study
Unit per milliliterBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Week After Dose 3: Booster Study10756.9 (8478.9 to 13647.0)10412.3 (7733.0 to 14020.0)
PrimaryGeometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Month After Dose 3: Booster Study

GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
1 Month after Dose 3
Reported as:
Geometric mean · Unit per milliliter
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Month After Dose 3: Booster Study
Unit per milliliterBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Month After Dose 3: Booster Study7983.0 (6266.0 to 10170.6)6676.9 (5242.6 to 8503.6)
PrimaryGeometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study

GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 week after Dose 3 to the geometric mean concentration of IgG at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
From 1 Month after Dose 2 to 1 Week after Dose 3
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study
Fold riseBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study1.6 (1.3 to 2.0)2.7 (1.3 to 5.9)
PrimaryGeometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study

GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 3 to the geometric mean concentration of IgG at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
From 1 Month after Dose 2 to 1 Month after Dose 3
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study
Fold riseBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study1.2 (1.0 to 1.5)1.8 (0.9 to 3.6)
PrimaryGeometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels Before Dose 3 to 1 Week After Dose 3: Booster Study

GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 week after Dose 3 to the geometric mean concentration of IgG before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Before Dose 3 to 1 Week after Dose 3
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels Before Dose 3 to 1 Week After Dose 3: Booster Study
Fold riseBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels Before Dose 3 to 1 Week After Dose 3: Booster Study5.9 (4.9 to 7.0)5.6 (4.4 to 7.2)
PrimaryGeometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels Before Dose 3 to 1 Month After Dose 3: Booster Study

GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 3 to the geometric mean concentration of IgG before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Before Dose 3 to 1 Month after Dose 3
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels Before Dose 3 to 1 Month After Dose 3: Booster Study
Fold riseBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels Before Dose 3 to 1 Month After Dose 3: Booster Study4.4 (3.7 to 5.2)3.6 (2.9 to 4.5)
PrimaryGeometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study

GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
From 1 Month after Dose 2 to 1 Week after Dose 3
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study
Fold riseBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study2.2 (1.6 to 3.0)1.7 (1.3 to 2.2)
PrimaryGeometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study

GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
From 1 Month after Dose 2 to 1 Month after Dose 3
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study
Fold riseBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study2.1 (1.6 to 2.7)1.2 (0.9 to 1.6)
PrimaryGeometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain Before Dose 3 to 1 Week After Dose 3: Booster Study

GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Before Dose 3 to 1 Week after Dose 3
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain Before Dose 3 to 1 Week After Dose 3: Booster Study
Fold riseBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain Before Dose 3 to 1 Week After Dose 3: Booster Study8.2 (5.3 to 12.7)5.7 (4.5 to 7.3)
PrimaryGeometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain Before Dose 3 to 1 Month After Dose 3: Booster Study

GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Before Dose 3 to 1 Month after Dose 3
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain Before Dose 3 to 1 Month After Dose 3: Booster Study
Fold riseBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain Before Dose 3 to 1 Month After Dose 3: Booster Study7.7 (5.6 to 10.7)4.2 (3.2 to 5.5)
PrimaryGeometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study

GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after dose 2. GMFRs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).

Time frame:
From 1 Month after Dose 2 to 1 Week after Dose 3

No measurements were reported for this outcome.

PrimaryGeometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study

GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after dose 2. GMFRs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).

Time frame:
From 1 Month after Dose 2 to 1 Month after Dose 3

No measurements were reported for this outcome.

PrimaryGeometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain Before Dose 3 to 1 Week After Dose 3: Booster Study

GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Before Dose 3 to 1 Week after Dose 3
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain Before Dose 3 to 1 Week After Dose 3: Booster Study
Fold riseBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain Before Dose 3 to 1 Week After Dose 3: Booster Study15.7 (11.2 to 22.0)18.4 (13.8 to 24.6)
PrimaryGeometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain Before Dose 3 to 1 Month After Dose 3: Booster Study

GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Before Dose 3 to 1 Month after Dose 3
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain Before Dose 3 to 1 Month After Dose 3: Booster Study
Fold riseBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain Before Dose 3 to 1 Month After Dose 3: Booster Study13.2 (9.6 to 18.1)15.0 (11.3 to 19.9)
PrimaryPercentage of Participants With Seroresponse to Reference Strain at 1 Month After Dose 2: Booster Study

Seroresponse was defined as greater than equal to (\>=) 4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of \>=4\*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
1 Month after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroresponse to Reference Strain at 1 Month After Dose 2: Booster Study
Percentage of participantsBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Percentage of Participants With Seroresponse to Reference Strain at 1 Month After Dose 2: Booster Study100 (87.2 to 100.0)100 (86.3 to 100.0)
PrimaryPercentage of Participants With Seroresponse to Reference Strain Before Dose 3: Booster Study

Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of \>=4\*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
Before Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroresponse to Reference Strain Before Dose 3: Booster Study
Percentage of participantsBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Percentage of Participants With Seroresponse to Reference Strain Before Dose 3: Booster Study92.6 (75.7 to 99.1)92.0 (74.0 to 99.0)
PrimaryPercentage of Participants With Seroresponse to Reference Strain 1 Week After Dose 3: Booster Study

Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of \>=4\*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
1 Week after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroresponse to Reference Strain 1 Week After Dose 3: Booster Study
Percentage of participantsBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Percentage of Participants With Seroresponse to Reference Strain 1 Week After Dose 3: Booster Study100.0 (87.2 to 100.0)100.0 (86.3 to 100.0)
PrimaryPercentage of Participants With Seroresponse to Reference Strain 1 Month After Dose 3: Booster Study

Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of \>=4\*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
1 Month after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroresponse to Reference Strain 1 Month After Dose 3: Booster Study
Percentage of participantsBNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Percentage of Participants With Seroresponse to Reference Strain 1 Month After Dose 3: Booster Study100.0 (87.2 to 100.0)100.0 (86.3 to 100.0)
PrimaryPercentage of Participants With Seroresponse to B.1.351 Variant Strain at 1 Month After Dose 2: Booster Study

Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.

Time frame:
1 Month after Dose 2

No measurements were reported for this outcome.

PrimaryPercentage of Participants With Seroresponse to B.1.351 Variant Strain Before Dose 3: Booster Study

Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.

Time frame:
Before Dose 3

No measurements were reported for this outcome.

PrimaryPercentage of Participants With Seroresponse to B.1.351 Variant Strain 1 Week After Dose 3: Booster Study

Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.

Time frame:
1 Week after Dose 3

No measurements were reported for this outcome.

PrimaryPercentage of Participants With Seroresponse to B.1.351 Variant Strain 1 Month After Dose 3: Booster Study

Seroresponse was defined as \>=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.

Time frame:
1 Month after Dose 3

No measurements were reported for this outcome.

SecondaryGeometric Mean Concentrations (GMCs) of Full-Length S-Binding IgG Levels at Baseline and 1 Month After Dose 2 for 30 mcg Dose of BNT162b2: Primary Study

GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\* LLOQ.

Time frame:
Baseline (before Dose 1), 1 Month after Dose 2
Reported as:
Geometric mean · Unit per milliliter
Geometric Mean Concentrations (GMCs) of Full-Length S-Binding IgG Levels at Baseline and 1 Month After Dose 2 for 30 mcg Dose of BNT162b2: Primary Study
Unit per milliliterBNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3Pooled US LotsBNT162b2 30 mcg: EU Lot
Baseline3.1 (2.7 to 3.5)2.6 (2.3 to 3.0)2.6 (2.2 to 3.0)2.8 (2.5 to 3.0)2.6 (2.1 to 3.2)
1 Month After Dose 26269.8 (5717.7 to 6875.2)6222.3 (5721.5 to 6766.9)6818.9 (6280.9 to 7403.1)6428.7 (6116.6 to 6756.8)6098.9 (5446.0 to 6830.1)
SecondaryGeometric Mean Fold Rises (GMFRs) in Full-Length S-Binding lgG Levels From Baseline to 1 Month After Dose 2 for 30 mcg Dose of BNT162b2: Primary Study

GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 2 to the geometric mean concentration of IgG at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
From Baseline (before Dose 1) up to 1 Month after Dose 2
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rises (GMFRs) in Full-Length S-Binding lgG Levels From Baseline to 1 Month After Dose 2 for 30 mcg Dose of BNT162b2: Primary Study
Fold riseBNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3Pooled US LotsBNT162b2 30 mcg: EU Lot
Geometric Mean Fold Rises (GMFRs) in Full-Length S-Binding lgG Levels From Baseline to 1 Month After Dose 2 for 30 mcg Dose of BNT162b2: Primary Study2036.6 (1744.5 to 2377.7)2367.1 (2028.6 to 2762.2)2645.2 (2271.2 to 3080.8)2331.9 (2133.7 to 2548.5)2373.8 (1901.2 to 2963.9)
SecondaryGeometric Mean Titers (GMT) of SARS-CoV-2 Neutralizing Titers at Baseline and 1 Month After Dose 2 for 20 mcg and 30 mcg Dose of BNT162b2 From US Lot 1: Primary Study

GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\* LLOQ.

Time frame:
Baseline (before Dose 1), 1 Month after Dose 2
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMT) of SARS-CoV-2 Neutralizing Titers at Baseline and 1 Month After Dose 2 for 20 mcg and 30 mcg Dose of BNT162b2 From US Lot 1: Primary Study
TiterBNT162b2 30 mcg: US Lot 1BNT162b2 20 mcg: US Lot 1
Baseline20.5 (20.5 to 20.5)20.5 (20.5 to 20.5)
1 Month after Dose 2969.6 (905.7 to 1038.0)913.0 (843.4 to 988.3)
SecondaryGeometric Mean Fold Rises (GMFRs) in SARS-CoV-2 Neutralizing Titers From Baseline to 1 Month After Dose 2 for 20 mcg and 30 mcg Dose of BNT162b2 From US Lot 1: Primary Study

GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 at 1 month after Dose 2 to the geometric mean titers of SARS-CoV-2 at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\* LLOQ.

Time frame:
From Baseline (before Dose 1) up to 1 Month after Dose 2
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rises (GMFRs) in SARS-CoV-2 Neutralizing Titers From Baseline to 1 Month After Dose 2 for 20 mcg and 30 mcg Dose of BNT162b2 From US Lot 1: Primary Study
Fold riseBNT162b2 30 mcg: US Lot 1BNT162b2 20 mcg: US Lot 1
Geometric Mean Fold Rises (GMFRs) in SARS-CoV-2 Neutralizing Titers From Baseline to 1 Month After Dose 2 for 20 mcg and 30 mcg Dose of BNT162b2 From US Lot 1: Primary Study47.3 (44.2 to 50.6)44.5 (41.1 to 48.2)

Adverse events

Collected over AEs and SAEs-For primary study: From Dose 1 to 1 Month after Dose 2 (up to a maximum of 2 months); For booster study: From Dose 3 to 1 Month after Dose 3 (up to a maximum of 35 days); Local reactions/systemic events: Within 7 days after each dose. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BNT162b2 30 mcg: US Lot 10/351 (0%)0/351 (0%)341/351 (97.2%)
BNT162b2 30 mcg: US Lot 20/352 (0%)0/352 (0%)336/352 (95.5%)
BNT162b2 30 mcg: US Lot 30/346 (0%)1/346 (0.3%)335/347 (96.5%)
BNT162b2 30 mcg: EU Lot0/173 (0%)1/173 (0.6%)165/173 (95.4%)
BNT162b2 20 mcg: US Lot 10/351 (0%)0/351 (0%)342/351 (97.4%)
BNT162b2 30 mcg: Booster Dose0/31 (0%)0/31 (0%)30/31 (96.8%)
BNT162b2.B.1.351 30 mcg: Booster Dose0/31 (0%)0/31 (0%)31/31 (100%)
Most frequent serious events
Most frequent serious events
EventBNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3BNT162b2 30 mcg: EU LotBNT162b2 20 mcg: US Lot 1BNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
MigrainosusNervous system disorders0/3510/3520/3461/1730/3510/310/31
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/3510/3521/3460/1730/3510/310/31
Most frequent other events
Showing 10 of 16
Most frequent other events
EventBNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3BNT162b2 30 mcg: EU LotBNT162b2 20 mcg: US Lot 1BNT162b2 30 mcg: Booster DoseBNT162b2.B.1.351 30 mcg: Booster Dose
Injection site painGeneral disorders319/351302/352316/347158/173314/35128/3129/31
FatigueGeneral disorders276/351259/352281/347133/173265/35121/3126/31
HeadacheNervous system disorders234/351229/352223/347119/173224/35113/3118/31
MyalgiaMusculoskeletal and connective tissue disorders136/351153/352150/34776/173142/35113/316/31
ChillsGeneral disorders115/351120/352129/34756/17392/3518/316/31
ArthralgiaMusculoskeletal and connective tissue disorders82/35196/35283/34742/17378/3514/314/31
DiarrhoeaGastrointestinal disorders57/35150/35248/34726/17354/3515/312/31
Injection site erythemaGeneral disorders16/35119/35223/3478/17316/3513/311/31
PyrexiaGeneral disorders26/35122/35229/34716/17320/3511/312/31
Injection site swellingGeneral disorders21/35131/35225/3478/17322/3512/312/31

Baseline characteristics

Safety Population comprising of all randomized participants who received at least 1 dose of the study intervention were included.

Age, Continuous
Age, Continuous(Years)BNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3BNT162b2 30 mcg: EU LotBNT162b2 20 mcg: US Lot 1Total
Mean28.0 ± 11.6627.8 ± 11.7627.5 ± 11.5427.7 ± 11.4027.5 ± 11.7127.7 ± 11.63
Sex: Female, Male
Sex: Female, Male(Participants)BNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3BNT162b2 30 mcg: EU LotBNT162b2 20 mcg: US Lot 1Total
Female17717615983163758
Male17417618790188815
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3BNT162b2 30 mcg: EU LotBNT162b2 20 mcg: US Lot 1Total
Hispanic or Latino4432552242195
Not Hispanic or Latino3063192911513091376
Unknown or Not Reported110002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BNT162b2 30 mcg: US Lot 1BNT162b2 30 mcg: US Lot 2BNT162b2 30 mcg: US Lot 3BNT162b2 30 mcg: EU LotBNT162b2 20 mcg: US Lot 1Total
American Indian or Alaska Native011035
Asian3648402444192
Native Hawaiian or Other Pacific Islander111025
Black or African American21161521468
White2862802831422831274
More than one race6554525
Unknown or Not Reported111104
08

Study locations

17 sites
  • Kaiser Permanente Oakland
    Oakland, California 94611, United States
  • Clinical Research Consulting
    Milford, Connecticut 06460, United States
  • Indago Research & Health Center, Inc
    Hialeah, Florida 33012, United States
  • Research Centers of America
    Hollywood, Florida 33024, United States
  • Clinical Neuroscience Solutions
    Orlando, Florida 32801, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Kentucky Pediatric/Adult Research
    Bardstown, Kentucky 40004, United States
  • Amici Clinical Research LLC
    Raritan, New Jersey 08869, United States
  • Accellacare - Wilmington
    Wilmington, North Carolina 28401, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45206, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229-3039, United States
  • Texas Center for Drug Development, Inc.
    Houston, Texas 77081, United States
  • Clinical Trials of Texas, LLC
    San Antonio, Texas 78229, United States
  • Martin Diagnostic Clinic
    Tomball, Texas 77375, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jul 2021, 5 months.

Results were first posted in Dec 2022, 1 year 5 months after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2021
First posted
Jan 19, 2021
StartActual
Feb 15, 2021
Primary completionActual
Jul 22, 2021
CompletionActual
Jul 22, 2021
Results first posted
Dec 22, 2022
Last update
Dec 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04713553
Lead sponsor
BioNTech SE
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jan 19, 2021
Start date
Feb 15, 2021
Primary completion
Jul 22, 2021
Completion
Jul 22, 2021
Results posted
Dec 22, 2022
Last update
Dec 22, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BNT162 Vaccine

Start the discussion